Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Genitourinary 1

Conditions

Prostatic Neoplasms 18Urinary Bladder Neoplasms 3Breast Neoplasms 2Recurrence 1Prostate Cancer Metastatic 1Parkinson Disease 1Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1Disease 1Carcinoma, Transitional Cell 1

Interventions

Magnetic Resonance Spectroscopy 10X-Rays 7Specimen Handling 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 6ulixertinib 3palbociclib 3larotrectinib 3erdafitinib 3Temozolomide 3tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ensartinib 2Vemurafenib 2Thalidomide 2Paclitaxel 2Nivolumab 2LY3023414 2Gemcitabine 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Positron Emission Tomography Computed Tomography × Genitourinary × Clear all
NCT06914427 2025-04-06

PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique

Xijing Hospital

Phase NA Not yet recruiting
35 enrolled
CNSGenitourinary

Glioma, Parkinson Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡